Finance & Capital Markets
-
A Look Behind, A Look Ahead With Allan Shaw
1/4/2021
The Business Of Biotech kicks off the new year with an up-close-and-personal talk with biotech investor and CFO extraordinaire Allan Shaw. We talk through last year's ups and downs and do a little prognosticating on what we're feeling bullish about--from unprecedented regulatory action to exciting progress on the cell and gene front--as we head into the new year.
-
CAR T Therapy Cost Control With Laurence Cooper, M.D., Ph.D.
10/26/2020
Controlling the cost of personalized medicine: We go behind the scenes of the effort to build a system that simplifies production and reduces the cost of non-viral T cell therapies with Ziopharm Oncology CEO Laurence Cooper, M.D., Ph.D.
-
True DEI Value in Biopharma with Arcellx's Rami Elghandour
6/16/2024
Asked about his company’s rapid rise since taking the helm in 2021, Arcellx CEO Rami Elghandour cites a few critical and risky decisions, the execution of some specific people on his all-star team, and a relentless commitment to diversity, equity, and inclusion. Before you skepticize, let me assure you: the man brings receipts.
-
BoB@JPM: Tom Chalberg, Ph.D., Genascence
2/23/2025
This episode of the Business of Biotech finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. Listen in as they discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts and bolts of the Genascence partnership strategy.
-
BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience
1/29/2025
From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way.
-
Biotech Is Back With Allan Shaw
1/24/2024
The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech builders. The results of that trip will feed the next several weeks of Business of Biotech podcast programming, and we're kicking things off with everyone's favorite life sciences CFO, Allan Shaw.
-
Pivoting To RNA With Circio's Dr. Erik Digman Wiklund
9/1/2024
This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer.
-
How To Be A CFO With Insmed's Sara Bonstein
4/9/2025
On today's episode of the Business of Biotech, we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to lead teams, especially when those teams have deeper subject matter expertise.
-
Public Sector Forged, Private Sector Tested With Renovaro BioSciences' Mark Dybul, M.D.
12/6/2023
During his leadership of the President's Emergency Plan for AIDS Relief during the George W. Bush administration, Dr. Mark Dybul, M.D. shepherded programs credited with saving more than 25 million lives. For many years after that public service drew to a close, he continued the mission as executive director of The Global Fund to Fight AIDS, Tuberculosis, and Malaria--working in lockstep with not only the world's leading scientists, but the likes of Bono and Sir Elton John along the way.
-
The Allogeneic Future with Poseida's Kristin Yarema, Ph.D.
8/4/2024
Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if their early autologous success can possibly live up to the promise of offering widespread accessibility to life-saving treatments. On this episode of the Business of Biotech, we'll learn about how the newly-appointed CEO of Poseida Therapeutics earned the company's reins, how Poseida is positioning itself to crack the allogeneic CAR T code, and how strategic collaborations with the likes of Astellas and Roche are fueling the effort.